3VG.F THERANEXUS EO -25

Healthcare Biotechnology Frankfurt Exchange
3.33 EUR
Close of Nov 11, 2026
1.51 4.49
Market cap
EUR 48.2M
P/E
-
P/B
15.77x
ROE
-103.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 3VG.F undervalued?

Graham number

The Graham number of THERANEXUS EO -25 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

THERANEXUS EO -25 fundamental analysis

No fundamental analysis for THERANEXUS EO -25 yet.

THERANEXUS EO -25 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About THERANEXUS EO -25

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pha…

Full company profile